Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (January 2025)
32 slides from Century Therapeutics's investor presentation, Jan 13, 2025
Slide 1: January 2025 Corporate Overview
January 2025 Corporate Overview
Slide 2: Forward-looking statements
2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts
Slide 3: Century's iPSC-derived cell types with Allo-Evasion stand apart from other allogeneic approaches
1 3 Century’s ability to create multiple iPSC-derived cell types incorporating Allo-Evasion stands apart from other allogeneic cell therapy approaches • Off-the-shelf therapies • Potential for improved time-to-treatment • Broad availability • Manufacturing dependability Engineerability • Control of
Slide 4: Century's capability to make multiple cell types enables matching to indication
4 Adaptive lymphocytes – capable of generating distinct functional attributes Greatest proliferative potential – potentially most useful for ongoing antigenic pressure GvHD risk, eliminated by knockout of T cell receptor (TCR) Potential for long-lived memory, mediating immune surveillance Bridge bet
Slide 5: Century is a leader in immune evasion engineering
5 Century is a leader in immune evasion engineering Continuous evolution of holistic protection from major immunity pathways Allo-Evasion 1.0 Allo-Evasion 3.0 Allo-Evasion 5.0 Protection from: Native T-cells Deletion of HLA-I Deletion of HLA-II Deletion of HLA-I Deletion of HLA-II Deletion of HLA-I
Slide 6: Allo-Evasion engineering aims to drive durable responses by enabling repeat dosing
6 Allo-Evasion engineering aims to drive durable responses by enabling repeat dosing for tighter control over drug exposure Ongoing clinical data from CNTY-101 in ELiPSE-1 show persistent exposure in the presence of an intact immune system1 With Allo-Evasion engineering Without Allo-Evasion engineer
Slide 7: Century is advancing a diverse iPSC pipeline across cell types and targets
7 Product iPSC Allo-Evasion Targets Indications Research IND-enabling Clinical P1 P2 P3 CNTY-101 iNK 1.0 CD19 B-cell malignancies Autoimmune diseases CNTY-308 iT 5.0 CD19 Autoimmune diseases B-cell malignancies CNTY-361 iT 5.0 BCMA Myasthenia gravis CNTY-102 iT 3.0 CD19 + CD22 B-cell malignancies CN
Slide 8: CNTY-101 CAR-iNK cell therapy with Allo-Evasion 1.0
CNTY-101 CAR-iNK cell therapy with Allo-Evasion 1.0
Slide 9: CNTY-101: A CD19-targeted CAR-iNK product designed for precise control of drug exposure
9 CNTY-101: A CD19-targeted CAR-iNK product designed to provide precise control of drug exposure and enable repeat dosing CNTY-101 off-the-shelf CAR-iNK cell therapy designed to treat patients with B cell-mediated diseases • Six precision gene edits • CD19-targeted CAR for B-cell depletion • Allo-Ev
Slide 10: CNTY-101 in R/R B-cell lymphomas aims to deliver durable responses via repeat dosing
10 CNTY-101 in relapsed/refractory B-cell lymphomas aims to deliver durable responses via repeat dosing Facilitated by Allo-Evasion and extending the period of pharmacologic pressure on tumor cells Unmet need: Potential solution from Century’s platform: • Autologous CD19 CAR-T is curative in ~40%1 o
Slide 11: ELiPSE-1 is a dose-escalating Phase 1 study of CNTY-101 in B-cell malignancies
11 ELiPSE-1 is a dose-escalating Phase 1 study of CNTY-101 in B-cell malignancies (NCT05336409) Patients with CD19+ aggressive and high-risk indolent R/R B-NHL • Part 1 – Dose escalation • Schedule A: Single dose • Schedule B: 1 dose per week x 3 weeks • Part 2 – Dose expansion DLBCL: Diffuse large
Slide 12: ELiPSE-1 enrolled heavily pre-treated R/R B-NHL patients
12 ELiPSE-1 enrolled heavily pre-treated R/R B-NHL patients ELiPSE-1 (NCT05336409) Phase 1 study in CD19+ B-cell Malignancies 1 As of 15 October 2024 data snapshot date, data collection ongoing DLBCL: Diffuse Large B Cell Lymphoma, HRFL: High-Risk Follicular Lymphoma; MCL: Mantle Cell Lymphoma, MZL:
Slide 13: CNTY-101 shows evidence of dose-responsive efficacy in ELiPSE-1 Phase 1
13 CNTY-101 shows evidence of dose-responsive efficacy in ELiPSE-1 Phase 1 Increased ORR at higher dose alongside a favorable safety profile ELiPSE-1 (NCT05336409) Phase 1 study in CD19+ B-cell Malignancies. As of 15 October 2024, data snapshot date, data collection ongoing, efficacy based on Lugano
Slide 14: CNTY-101 exposure increases with dose and schedule
14 PBMC genomic DNA Plasma cell-free DNA CNTY-101 exposure increases with dose and schedule • Extended persistence in circulation at dose level 4A (3 x 10e9 cell infusion) • Persistence outside the bloodstream was detected via a cell-free (cf) DNA assay beyond day 15 • Multiple infusions in Schedule
Slide 15: CNTY-101 shows persistence in the presence of a restored immune system
15 • Lymphodepleting Chemotherapy (LDC) depleted patient NK/T cell counts and drove a transient spike of IL-15 cytokine • By post-infusion day 8, NK/T cell counts, IL-15 concentration returned to screening level • Similar PK profile observed for each CNTY-101 infusion within a cycle despite evident
Slide 16: CNTY-101 treatment demonstrates rapid B-cell depletion
16 CNTY-101 treatment demonstrates rapid B-cell depletion and was associated with naive non-class switched profile of re-emergent B-cells Data in r/r NHL patients supports the application of CNTY-101 in autoimmune diseases B-cell depletion Re-emergent B-cell profile Rapid and effective depletion of
Slide 17: ELiPSE-1 initial data validates Century's iPSC platform
17 ELiPSE-1 initial data validates Century’s iPSC platform Heavily pretreated and refractory patient population treated in first-in-human dose escalation trial, including ~50% patients who had received prior CAR T treatments Favorable initial safety profile; can be delivered in an outpatient setting
Slide 18: Autoimmune disorders present significant unmet medical need
18 Autoimmune disorders present significant unmet medical need Systemic Lupus Erythematosus (SLE) Lupus Nephritis (LN) Idiopathic Inflammatory Myopathy (IIM) Diffuse cutaneous Systemic Sclerosis (dcSSc) Characteristics Multiorgan, potentially fatal, inflammatory disease with risk for organ damage, i
Slide 19: Clear opportunity for allogeneic cell therapies in autoimmune indications
19 Clear opportunity for allogeneic cell therapies to address moderate to severe autoimmune indications by providing long-term, drug-free remission Significant patient population and unmet need • Tens of thousands of patients with unmet need in the US • Heterogeneous nature of patients with autoimmu
Slide 20: CNTY-101 is a differentiated autoimmune disease treatment
20 Allogeneic iPSC • Available “off-the-shelf” • No patient apheresis required • No manufacturing wait time • Batch-to-batch consistency • Platform enables lower COGs than donor-derived or autologous NK cells • Killing potency (≥ primary CAR-T) leads to deep B-cell depletion1 • Trafficking to second
Slide 21: CNTY-101 eliminates B cells with greater potency than primary CAR-T cells
21 In vitro studies show that CNTY-101 eliminates B cells with greater potency than primary CAR-T cells https://www.centurytx.com/wp-content/uploads/ASH_Chin_Natural-Killer-GD-Cells-Final.pdf Isolated B cells or CD19+ target cells were co-cultured with CNTY-101 or primary CAR-T at several E:Ts in 96
Slide 22: CALiPSO-1 is a Phase 1 study of CNTY-101 in refractory autoimmune diseases
22 CALiPSO-1 is a Phase 1 study of CNTY-101 in refractory B cell-mediated autoimmune diseases (NCT06255028) infusions in outpatient setting Inclusion: • Participants with moderate to severe SLE, LN, IIM, or dcSSc with treatment-resistant and active disease, after 2+ standard immunosuppressive therap
Slide 23: CNTY-308 CAR αβ-iT cell with Allo-Evasion 5.0
CNTY-308 CAR αβ-iT cell with Allo-Evasion 5.0
Slide 24: CNTY-308 is an iPSC-derived CD19-targeted CAR-iT with preclinical efficacy comparable to autologous CAR-T
24 CNTY-308 is an iPSC-derived CD19-targeted CAR-iT with preclinical efficacy comparable to autologous CD19 CAR-T cells 1. https://www.centurytx.com/wp-content/uploads/ASH_Heinze_iPSC-Derived-CD4-CD8-Final.pdf CD4+/CD8+ iT-cell • CD19-targeted CAR to target B-cells for cytotoxic depletion • 4-1BB an
Slide 25: iPSC-CAR-T cells display functional characteristics of adult primary T cells
25 Century’s iPSC-CAR-T cells display the functional characteristics of adult primary T cells: In vitro activity Effective T cell therapies require the generation of iPSC-CAR-T cells with three key in vitro cell functions Cytotoxicity: Effector function Cell expansion and persistence Therapeutic eff
Slide 26: In preclinical animal studies, iPSC-CAR-T cells show comparable activity to primary CAR-T
26 1e+06 1e+07 1e+08 1e+09 1e+10 0 10 20 30 40 Days Post−Effector Infusion Luminescence (log axis) Group PBS only 1' CAR−T iPS−CAR−T Group 1: PBS only Group 2: 1' CAR−T Group 3: iPS−CAR−T 0 10 20 30 0 10 20 30 0 10 20 30 1e+07 1e+09 1e+11 Days Post−Effector Infusion Luminescence (log axis) In precli
Slide 27: CENTURY Platform: iPSC cell foundry
CENTURY Platform: iPSC cell foundry THERAPEUTICS
Slide 28: Century's robust pre-clinical pipeline
28 Century’s robust pre-clinical pipeline has potential to address critical barriers confronting cellular therapies Multiple iPSC-derived immune effector cells iPSC-enabled engineering solutions Opportunity across multiple diseases • Cytokine engineering to reduce or eliminate lymphodepletion • Enha
Slide 29: Precision CRISPR MAD7-mediated sequential gene editing of iPSCs
29 Precision CRISPR MAD7-mediated sequential gene editing of iPSCs generates uniform product candidates Multiple gene edits (KO/KI) iPSC Engineered iPSC Master Cell Bank (MCB) Sequential selection steps iPSC Precision Engineering CRISPR-mediated HDR (MAD 7) Advantages of Century’s Platform Precise C
Slide 30: Century platform and in-house manufacturing
30 Century platform and in-house manufacturing: Pathway to scalable, profitable cell therapy Established in-house manufacturing from development to launch Quality product at disruptive scale and cost of goods • Built-for-purpose 53,000 ft2 cGMP facility • Key leaders each with 1–2 decades of cell th
Slide 31: Century Therapeutics is advancing next-generation iPSC-derived allogeneic NK and T cell therapies
31 Century Therapeutics is advancing next-generation iPSC-derived allogeneic NK and T cell therapy candidates for the treatment of cancer and autoimmunity Ended FY24 with cash, cash equivalents, and investments of ~$220M (unaudited*) Cash runway into 2H26 Differentiated pipeline based on iPSC and Al
Slide 32: THERAPEUTICS a
THERAPEUTICS a ) CENTURY nturytx.com
Century Therapeutics — Investor Presentation (January 2025) on 6ix